Abstract Number: 1596 • ACR Convergence 2020
Coproduction of Care for Veterans with RA: Improving Elicitation and Documentation of Patient Goals
Background/Purpose: Coproduction of healthcare services offers a pathway to increase patient engagement in care. Patients and clinicians coproduce care by working together to: (1) co-assess…Abstract Number: 1842 • ACR Convergence 2020
Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus: Post Hoc Analyses of Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial
Background/Purpose: Repository corticotropin injection (RCI, Mallinckrodt Pharmaceuticals) is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides approved for the treatment…Abstract Number: 0143 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis Who Are Methotrexate-naïve: Results from the FINCH-3 Study
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor currently being investigated as an agent to treat rheumatoid arthritis (RA). In the…Abstract Number: 0186 • ACR Convergence 2020
The Number of Associated Comorbidities Can Impact Disease Activity Scores Independently from Objective Measures of Inflammation in Patients with Rheumatoid Arthritis
Background/Purpose: Disease activity scores (DAS) are used as tools to assess persistent inflammation and need for therapeutic escalation in patients with Rheumatoid arthritis (RA). One…Abstract Number: 0356 • ACR Convergence 2020
Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes and…Abstract Number: 0863 • ACR Convergence 2020
Residual Treatment Burden, Desired Improvement, and Prioritized Treatment Goals in Systemic Lupus Erythematosus (SLE): Results from the SLE-UPDATE (Understanding Preferences, Disease Activity and Treatment Expectations) Survey in the United States
Background/Purpose: Literature describes a fairly high degree of satisfaction with SLE therapies, despite patients reporting high rates of adverse event (1-2). The objectives of this…Abstract Number: 1177 • ACR Convergence 2020
Rheumatic Diseases in Mexican Children and Their Psychosocial and Economic Impact on Caregivers
Background/Purpose: Pediatric rheumatic diseases (PRD) are a heterogeneous group of disorders. PRD patients and their caregivers face a number of challenges, these include the consequences…Abstract Number: 1290 • ACR Convergence 2020
A Multitrait-Multimethod Matrix Approach to the Construct Validity of Patient Reported Outcomes Measurement Information System Computerized (PROMIS) Adaptive Tests (CAT) in Systemic Lupus Erythematous
Background/Purpose: Use of The Patient Reported Outcomes Measurement Information System computerized adaptive test (PROMIS-CAT) in adults with systemic lupus erythematous (SLE) is an emerging research…Abstract Number: 1599 • ACR Convergence 2020
Workflows for Collecting and Using Patient-reported Outcomes Across Rheumatology Practices
Background/Purpose: The use of patient reported outcomes (PROs) during rheumatology visits may facilitate shared decision making and encourage patients to share their health goals. However,…Abstract Number: 1866 • ACR Convergence 2020
Patient-reported Impact of Axial Spondyloarthritis on Working Life. Results from the Spanish Atlas 2017
Background/Purpose: Axial spondyloarthritis (axSpA) impacts negatively on multiple dimensions of patient’s life, including their working life. The present study aims to evaluate working status, work-related…Abstract Number: 0144 • ACR Convergence 2020
Age, Income, Education, and Health Conditions Are Associated with Patient Empowerment Among US Adults with Arthritis, but Race and Geography Are Not
Background/Purpose: The purpose of this study is to understand experiences of empowerment in healthcare visits among US adults with arthritis, and key factors associated with discrepancies…Abstract Number: 0206 • ACR Convergence 2020
Fifty-Two Week Outcomes of Biologic-Naïve RA Patients Treated with Subcutaneous Abatacept in Japanese Multicenter Investigational Study (ORIGAMI Study)
Background/Purpose: Long-term clinical benefit and patient-reported outcomes (PRO) of subcutaneously-injected abatacept (ABA) in patients with RA in a real-world setting are of therapeutic interest. We…Abstract Number: 0358 • ACR Convergence 2020
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from German Observational Study
Background/Purpose: There is growing body of evidence that smoking is associated with more active and severe disease in patients (pts) with ankylosing spondylitis (AS)1,2. The…Abstract Number: 0873 • ACR Convergence 2020
Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Background/Purpose: When deciding to start patients with PsA on biologic therapy, rheumatologists may focus on skin involvement in addition to joint symptoms. The purpose of…Abstract Number: 1201 • ACR Convergence 2020
Effect of Filgotinib on Pain in Patients with Rheumatoid Arthritis: Results from Phase 3 Clinical Trials
Background/Purpose: RA patients (pts) often suffer substantial pain despite ongoing treatment (tx) and regard pain control as a top tx goal. Filgotinib (FIL)—a potent, oral…
ACR Meeting Abstracts